Answers are grounded in this paper and cite their sources.
Our results suggest that HAART can be successfully used in African populations with elevated baseline immune activation markers.
No takes yet. Share an insight, caveat, or question.
Koblavi‐Dème et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: